Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

## **Product Information**

Product ID G1408

CAS No. 879085-55-9

**Chemical Name** 

Synonym GDC0449, Vismodegib

Formula C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S

Formula Wt. 421.30

**Melting Point** 

Purity ≥98%

Solubility DMSO 84 mg/mL (199.38

mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

Description GDC-0449 is an inhibitor of Smo that prevents downstream hedgehog (Hh) signaling. GDC-0449 exhibits anticancer

chemotherapeutic activity; it is currently approved to treat basal cell carcinoma and is in clinical trials as a potential treatment for other cancers. GDC-0449 inhibits cell motility, invasion, and colony formation in basal cell carcinoma cells.

Bulk quanitites available upon request

Product ID Size G1408 25 mg G1408 100 mg

References Islam SS, Mokhtari RB, Noman AS, et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol Carcinog. 2015 Mar 1. [Epub ahead of print]. PMID: 25728352.

> Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of Hedgehog pathway and Vismodegib in the management of Basal Cell Carcinoma. Curr Med Res Opin. 2015 Feb 17:1-45. PMID: 25690490.

Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45. PMID: 25278454.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.